Portfolio Lab

AbbVie Inc.

  • Stock
  • Ticker ABBV
  • ISIN US00287Y1091
  • NYSE

Health care · Pharmaceuticals · USA

$286.20 +0.94%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of AbbVie Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ABBVGlobal equities (VT)

$10,000 grew to $71,213. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −45.1% in 08/2019, measured from the peak in 01/2018. It took 34 months to get back to the old peak.

1-year return
+28.5%
5-year return p.a.
+24.1%
10-year return p.a.
+21.7%
Volatility p.a.
25.4%
Largest decline
−45.1%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue15,10213,34315,42315,77616,61815,00216,99017,404
Gross profit10,7069,34111,07710,47212,06610,78412,69913,119
Operating income-1,4903,7334,8941,9044,5443,9906,4326,267
EBITDA-1,2843,9145,0802,0964,7474,1786,6266,459
Net income-221,2869381861,8166953,6134,218
Earnings per share-0.020.720.520.101.020.392.032.37
Balance sheet
Total assets135,161136,165137,182133,898133,960136,463135,115147,680
Liabilities131,797134,703137,320136,497137,188143,075141,003152,218
Equity3,3251,420-183-2,642-3,270-6,656-5,935-4,583
Cash5,5245,1756,4675,6295,2299,3916,56910,774
Long-term debt66,841–––64,503–––
Cash flow
Operating cash flow7,0481,6355,1537,0245,2183,8293,4367,606
Capital expenditure-291-235-269-381-329-265-322-301
Free cash flow6,7571,4004,8846,6434,8893,5643,1147,305

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +60.1%, weakest 2018 at −1.0%. 7 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
3 Nov 2026$2.37
3 Aug 2026$2.03
8 May 2026$0.39
20 Feb 2026$1.02
4 Nov 2025$0.10
4 Aug 2025$0.52
9 May 2025$0.72
14 Feb 2025−$0.02
4 Nov 2024$0.88
7 Aug 2024$0.77
3 May 2024$0.77
20 Feb 2024$0.46

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€458bn
Market cap in trading currency
$506bn
Enterprise value
$495bn
P/E
49.3
P/S
7.66
P/B
–
EV/Sales
7.50
EV/EBITDA
22.5
Earnings yield
2.0%
FCF yield
3.7%

Results (last four quarters)

Revenue
$66.0bn
Gross profit
$48.7bn
EBITDA
$22.0bn
Net income
$10.3bn
Earnings per share
$5.81
Revenue per share
$37.35
Revenue growth
+10.3%
Earnings growth
+2,167.7%

Profitability

Gross margin
73.7%
Operating margin
32.2%
Net margin
15.7%
Return on equity
–
Return on assets
7.0%

Balance sheet and cash flow

Cash
$10.8bn
Cash per share
$6.10
Financial debt
$0
Debt/equity %
–
Current ratio
0.87
Book value per share
−$2.59
Operating cash flow
$20.1bn
Free cash flow
$18.9bn

Dividend

Dividend yield
2.42%
Dividend (12 months)
$6.92
Yield (12 months)
2.42%
Payout ratio
119%
Ex-dividend date
15 Oct 2026

Shares and trading

Shares outstanding
1.77bn
Volume
8.67m
Avg. volume 3 months
4.80m
Relative volume
1.8

Price and technicals

Price
$286.20
1 day
+0.9%
52-week high
$295.03
52-week low
$197.38
Distance to 52-week high
−3.0%
Distance to 52-week low
+45.0%
Distance to 50-day line
+2.6%
Distance to 200-day line
+18.0%
RSI (14)
49
Volatility 1M
20.7%

Performance

1 week
−3.0%
1 month
+0.4%
3 months
+8.2%
6 months
+32.7%
YTD
+25.3%
1 year
+22.9%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ABBV performed since 11/2016?

$10,000 grew to $71,213 by 20 Nov 2026, which is +21.7% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ABBV?

Volatility was 25.4% per year, measured on monthly returns. The largest decline from a peak was −45.1%, with the low in 08/2019.

How does ABBV compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, ABBV returned +21.7% at 25.4%. The correlation of monthly returns was 0.34; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

AbbVie Inc. (ABBV): Return and risk | Portfolio Lab